SIS
CLDX icon

Strategic Investment Solutions’s Celldex Therapeutics CLDX Stock Holding History

Strategic Investment Solutions’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5
Closed -$136 – 673
2025
Q4 		$136 Hold
5
– – ﹤0.01% 608
2025
Q3 		$129 Hold
5
– – ﹤0.01% 584
2025
Q2 		$102 Hold
5
– – ﹤0.01% 580
2025
Q1 		$91 Hold
5
– – ﹤0.01% 610
2024
Q4 		$198 Hold
5
– – ﹤0.01% 612
2024
Q3 		$170 Hold
5
– – ﹤0.01% 611
2024
Q2 		$191 Buy
+5
New +$189 ﹤0.01% 577
2023
Q4 		$198 Buy
+5
New +$147 ﹤0.01% 1082
2023
Q2 		– Sell
-5
Closed -$180 – 888
2023
Q1 		$180 Buy
+5
New +$216 ﹤0.01% 981

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Strategic Investment Solutions's CLDX Position: Q1 2026 in Review

Strategic Investment Solutions sold out of Celldex Therapeutics (CLDX) in Q1 2026, closing a stake of 5 shares — an estimated $136 sold.

Strategic Investment Solutions first reported a position in CLDX in Q1 2023 and held it in 9 quarters. The position peaked at $198 in Q4 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Strategic Investment Solutions reported no remaining Celldex Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Strategic Investment Solutions sold 5 Celldex Therapeutics shares in Q1 2026, an estimated $136.
  • Strategic Investment Solutions first reported a position in Celldex Therapeutics in Q1 2023 and held it in 9 quarters.
  • Strategic Investment Solutions's Celldex Therapeutics position peaked at $198 in Q4 2024.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Strategic Investment Solutions's 13F filing for Q1 2026, filed 1 May 2026.